palmitoylethanolamide.com.au
HomeResearchDavis 2019

The Potential Benefits of Palmitoylethanolamide in Palliation: A Qualitative Systematic Review

Davis MP, Behm B, Mehta Z, Fernandez C. Am J Hosp Palliat Care. 2019;36(12):1134-1154.

ReviewHumans

Design
Review
Subjects
Qualitative systematic review
Dose used in the study
Not applicable
Duration
Not applicable
What was measured
Trials of palmitoylethanolamide relevant to palliative care: pain, depression, Parkinson's disease, stroke, autism; adverse effects and interactions

What the authors reported

A significant number of trials show pain relief, with weaker evidence for non-pain symptoms, no reported drug interactions and few adverse effects; the authors note little is known about pharmacokinetics.

Limits of this study

Qualitative, so no pooled estimate. Written by an independent US palliative care group. Its comment that no interactions are reported reflects absence of study, not evidence of safety; see the safety page.

Source

PubMed 31113223 · doi:10.1177/1049909119850807

Entry checked against the abstract on PubMed on 2026-09-22. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.